KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abbott Laboratories (ABT) Operating Expenses (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Operating Expenses for 17 consecutive years, with $9.2 billion as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 1.6% to $9.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $36.3 billion through Dec 2025, up 3.27% year-over-year, with the annual reading at $36.3 billion for FY2025, 3.27% up from the prior year.
  • Operating Expenses hit $9.2 billion in Q4 2025 for Abbott Laboratories, down from $9.3 billion in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $9.3 billion in Q3 2025 to a low of $8.2 billion in Q1 2023.
  • Historically, Operating Expenses has averaged $8.7 billion across 5 years, with a median of $8.7 billion in 2024.
  • Biggest five-year swings in Operating Expenses: surged 32.68% in 2021 and later decreased 8.29% in 2023.
  • Year by year, Operating Expenses stood at $9.1 billion in 2021, then fell by 3.33% to $8.8 billion in 2022, then decreased by 3.71% to $8.5 billion in 2023, then rose by 7.11% to $9.1 billion in 2024, then increased by 1.6% to $9.2 billion in 2025.
  • Business Quant data shows Operating Expenses for ABT at $9.2 billion in Q4 2025, $9.3 billion in Q3 2025, and $9.1 billion in Q2 2025.